Recent advances in the design and development of novel negative allosteric modulators of mGlu 5

ACS Chemical Neuroscience

Volumn 2, Issue 8, 2011, Pages 411-432

  Emmitte, Kyle A ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

addiction; anxiety; fragile X syndrome; gastresophageal reflux disease; Metabotropic glutamate receptor 5; negative allosteric modulator; pain; Parkinsons disease

Indexed keywords

1,2,4 TRIAZOLE DERIVATIVE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; ADX 10059; ADX 48621; AFQ 056; AZD 2066; AZD 2516; DIPYRONE; FENOBAM; ISOXAZOLE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 5 ANTAGONIST; METABOTROPIC RECEPTOR 5 NEGATIVE ALLOSTERIC MODULATOR; METABOTROPIC RECEPTOR ANTAGONIST; OXADIAZOLE DERIVATIVE; OXIME DERIVATIVE; RG 7090; STX 107; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ADDICTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; BINDING AFFINITY; DRUG PENETRATION; DRUG POTENCY; DRUG STRUCTURE; FRAGILE X SYNDROME; GASTROESOPHAGEAL REFLUX; HUMAN; MIGRAINE; NONHUMAN; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

EID: 80051710347     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn2000266     Document Type: Review

References (104)

1. Schoepp, D. D., Jane, D. E., and Monn, J. A. (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors Neuropharmacology 38, 1431-1476 (Pubitemid 29457728)
2. Conn, P. J. and Pin, J.-P. (1997) Pharmacology and functions of metabotropic glutamate receptors Annu. Rev. Pharmacol. Toxicol. 37, 205-237 (Pubitemid 27238875)
3. Knöpfel, T., Kuhn, R., and Allgeier, H. (1995) Metabotropic glutamate receptors: Novel targets for drug development J. Med. Chem. 38, 1417-1426
4. Niswender, C. M., Jones, C. K., and Conn, P. J. (2005) New therapeutic frontiers for metabotropic glutamate receptors Curr. Top. Med. Chem. 5, 847-857 (Pubitemid 41269559)
5. Ritzén, A., Mathiesen, J. M., and Thomsen, C. (2005) Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators Basic Clin. Pharmacol. Toxicol. 97, 202-213 (Pubitemid 41435091)
6. Kew, J. N. C. (2004) Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential Pharmacol. Ther. 104, 233-244 (Pubitemid 39531928)
7. Gasparini, F., Lingenhöhl, K., Stoehr, N., Flor, P. J., Heinrich, M., Vranesic, I., Biollaz, M., Allgeier, H., Heckendorn, R., Urwyler, S., Varney, M. A., Johnson, E. C., Hess, S. D., Rao, S. P., Sacaan, A. I., Santori, E. M., Veliocelebi, G., and Kuhn, R. (1999) Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systematically active mGlu5 receptor antagonist Neuropharmacology 38, 1493-1503 (Pubitemid 29457731)
8. Cosford, N. D., Tehrani, L., Roppe, J., Schweiger, E., Smith, N. D., Anderson, J., Bristow, L., Brodkin, J., Jiang, X., McDonald, I., Rao, S., Washburn, M., and Varney, M. A. (2003) 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]- pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity J. Med. Chem. 46, 204-206 (Pubitemid 36078139)
9. Zhu, C. Z., Wilson, S. G., Mikusa, J. P., Wismer, C. T., Gauvin, D. M., Lynch, J. J., Wade, C. L., Decker, M. W., and Honore, P. (2004) Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities Eur. J. Pharmacol. 506, 107-118 (Pubitemid 39592907)
10. Nicolas, L. B., Kolb, Y., and Prinssen, E. P. M. (2006) A combined marble burying-locomoter activity test in mice: A practical screening test with sensitivity to different classes of anxiolytics and antidepressants Eur. J. Pharmacol. 547, 106-115 (Pubitemid 44373902)
11. Pietraszek, M., Sukhanov, I., Maciejak, P., Szyndler, J., Gravius, A., Wislowska, A., Plaznik, A., Bespalov, A. Y., and Danysz, W. (2005) Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats Eur. J. Pharmacol. 514, 25-34 (Pubitemid 40692760)
12. Busse, C. S., Brodkin, J., Tattersall, D., Anderson, J. J., Warren, N., Tehrani, L., Bristow, L. J., Varney, M. A., and Cosford, N. D. P. (2004) The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety Neuropsychopharmacology 29, 1971-1979 (Pubitemid 39486548)
13. A signaling Neuropharmacology 47, 342-350 (Pubitemid 38953225)
14. Spooren, W. P. J. M., Vassout, A., Neijt, H. C., Kuhn, R., Gasparini, F., Roux, S., Porsolt, R. D., and Gentsch, C. (2000) Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6- (phenylethynyl)pyridine in rodents J. Pharmacol. Exp. Ther. 295, 1267-1275
15. Jensen, J., Lehmann, A., Uvebrant, A., Carlsson, A., Jerndal, G., Nilsson, K., Frisby, C., Blackshaw, L. A., and Mattsson, J. P. (2005) Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist Eur. J. Pharmacol. 519, 154-157 (Pubitemid 43181178)
16. Frisby, C. L., Mattsson, J. P., Jensen, J. M., Lehmann, A., Dent, J., and Blackshaw, L. A. (2005) Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands Gastroenterology 129, 995-1004 (Pubitemid 41242690)
17. de Vrij, F. M. S., Levenga, J., van der Linde, H. C., Koekkoek, S. K., De Zeeuw, C. I., Nelson, D. L., Oostra, B. A., and Willemsen, R. (2008) Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice Neurobiol. Dis. 31, 127-132 (Pubitemid 351822560)
18. Yan, Q. J., Rammal, M., Tranfaglia, M., and Bauchwitz, R. P. (2005) Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP Neuropharmacology 49, 1053-1066 (Pubitemid 41503304)
19. McGeehan, A. J. and Olive, M. F. (2003) The mGluR5 antagonist MPEP reduces the conditioned rewarding effects of cocaine but not other drugs of abuse Synapse 47, 240-242 (Pubitemid 36056837)
20. Chiamulera, C., Epping-Jordan, M. P., Zocchi, A., Marcon, C., Cottiny, C., Tacconi, S., Corsi, M., Orzi, F., and Conquet, F. (2001) Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice Nat. Neurosci. 4, 873-874 (Pubitemid 32801588)
21. Martin-Fardon, R., Baptista, M. A. S., Dayas, C. V., and Weiss, F. (2009) Dissociation of the effects of MTEP [3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl] piperidine] on conditioned reinstatement and reinforcement: Comparison between cocaine and a conventional reinforcer J. Pharmacol. Exp. Ther. 329, 1084-1090
22. Kumaresan, V., Yuan, M., Yee, J., Famous, K. R., Anderson, S. M., Schmidt, H. D., and Pierce, R. C. (2009) Metabotropic glutamate receptor 5 (mGluR5) antagonists attenuate cocaine priming- and cue-induced reinstatement of cocaine seeking Behav. Brain Res. 202, 238-244
23. Bäckstrom, P. and Hyytiä, P. (2006) Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking Neuropsychopharmacology 31, 778-786
24. Iso, Y., Grajkowska, E., Wroblewski, J. T., Davis, J., Goeders, N. E., Johnson, K. M., Sanker, S., Roth, B. L., Tueckmantel, W., and Kozikowski, A. P. (2006) Synthesis and structure-activity relationships of 3-[(2-Methyl-1,3- thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; search for cocaine medications J. Med. Chem. 49, 1080-1100 (Pubitemid 43221655)
25. Kenny, P. J., Boutrel, B., Gasparini, F., Koob, G. F., and Markou, A. (2005) Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats Psychopharmacology 179, 247-254 (Pubitemid 40576712)
26. Tessari, M., Pilla, M., Andreoli, M., Hutcheson, D. M., and Heidbreder, C. A. (2004) Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking Eur. J. Pharmacol. 499, 121-133 (Pubitemid 39201219)
27. Platt, D. M., Rowlett, J. K., and Spealman, R. D. (2008) Attenuation of cocaine self-administration in squirrel monkeys following repeated administration of the mGluR5 antagonist MPEP: comparison with dizocilpine Psychopharmacology 200, 167-176
28. Lee, B., Platt, D. M., Rowlett, J. K., Adewale, A. S., and Spealman, R. D. (2005) Attenuation of behavioral effects of cocaine by the metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)-pyridine in squirrel monkeys: Comparison with dizocilpine J. Pharmacol. Exp. Ther. 312, 1232-1240 (Pubitemid 40293785)
29. Tronci, V., Vronskaya, S., Montgomery, N., Mura, D., and Balfour, D. J. K. (2010) The effects of the mGluR5 receptor antagonist 6-methyl-2- (phenylethynyl)-pyridine (MPEP) on behavioural responses to nicotine Psychopharmacology 211, 33-42
30. Kotlinska, J. and Bochenski, M. (2007) Comparison of the effects of mGluR1 and mGluR5 antagonists on the expression of behavioral sensitization to the locomotor effect of morphine and the morphine withdrawal jumping in mice Eur. J. Pharmacol. 558, 113-118 (Pubitemid 46328885)
31. Gass, J. T., Osborne, M. P. H., Watson, N. L., Brown, J. L., and Olive, M. F. (2009) mGluR5 antagonism attenuates methamphetamine reinforcement and prevents reinstatement of methamphetamine-seeking behavior in rats Neuropsychopharmacology 34, 820-833
32. Adams, C. L., Short, J. L., and Lawrence, A. J. (2010) Cue-conditioned alcohol seeking in rats following abstinence: Involvement of metabotropic glutamate 5 receptors Br. J. Pharmacol. 159, 534-542
33. Besheer, J., Grondin, J. J. M., Salling, M. C., Spanos, M., Stevenson, R. A., and Hodge, C. W. (2009) Interoceptive effects of alcohol require mGlu5 receptor activity in the nucleus accumbens J. Neurosci. 29, 9582-9591
34. Gass, J. T. and Olive, M. F. (2009) Role of protein kinase C epsilon (PKCε) in the reduction of ethanol reinforcement due to mGluR5 antagonism in the nucleus accumbens shell Psychopharmacology 204, 587-597
35. 1/2 phosphorylation in specific limbic brain regions: Blockade by the mGluR5 antagonist MPEP Neuropharmacology 55, 546-554
36. Lominac, K. D., Kapasova, Z., Hannun, R. A., Patterson, C., Middaugh, L. D., and Szumlinski, K. K. (2006) Behavioral and neurochemical interactions between group 1 mGluR antagonists and ethanol: Potential insight into their anti-addictive properties Drug Alcohol Depend 85, 142-156 (Pubitemid 44441668)
37. Morin, N., Grégoire, L., Gomez-Mancilla, B., Gasparini, F., and Di Paolo, T. (2010) Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in Parkinsonian monkeys Neuropharmacology 58, 981-986
38. Lindsley, C. W. and Emmitte, K. A. (2009) Recent progress in the discovery and development of negative allosteric modulators of mGluR5 Curr. Opin. Drug Discovery Dev. 12, 446-457
39. Gasparini, F., Bilbe, G., Gomez-Mancilla, B., and Spooren, W. (2008) mGluR5 antagonists: Discovery, characterization and drug development Curr. Opin. Drug Discovery Dev. 11, 655-665
40. Jaeschke, G., Wettstein, J. G., Nordquist, R. E., and Spooren, W. (2008) mGluR5 receptor antagonists and their therapeutic potential Expert Opin. Ther. Pat. 18, 123-142 (Pubitemid 351377052)
41. Rocher, J.-P. (2010) Discovery of novel series of selective mGluR5 negative allosteric modulators. Metabotropic glutamate receptors: Translation from discovery to clinical trials, New York, NY, February 23, 2010; The New York Academy of Sciences, New York.
42. Keywood, C., Wakefield, M., and Tack, J. (2009) A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastroesophageal reflux disease Gut 58, 1192-1199
43. Marin, J. C. A. and Goadsby, P. J. (2010) Glutamatergic fine tuning with ADX-10059: A novel therapeutic approach for migraine? Exp. Opin. Invest. Drugs 19, 555-561
44. Goadsby, P. J. and Keywood, C. G. (2009) Investigation of the role of mGluR5 inhibition in migraine: A proof of concept study of ADX10059 in acute treatment of migraine. Abstracts of Papers, 61st annual meeting of the American Academy of Neurology, Seattle, WA, Abstract P06.006, American Academy of Neurology, Saint Paul, MN.
45. Pecknold, J. C., McClure, D. J., Appeltauer, L., Wrzesinski, L., and Allan, T. (1982) Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study J. Clin. Psychopharmacol. 2, 129-132
46. Berry-Kravis, E. M., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchinson, J., Snape, M., Tranfaglia, M., Nguyen, D. V., and Hagerman, R. (2009) A pilot open label, single dose trial of fenobam in adults with fragile X syndrome J. Med. Genet. 46, 266-271
47. Gasparini, F. (2009) mGluR5 antagonists as potential symptomatic therapy for Fragile X Disorder. Abstracts of Papers, 239th ACS national meeting, San Francisco, CA, Abstract MEDI 12031, American Chemical Society: Washingtion, DC.
48. Berg, D., Godau, J., Trenkwalder, C., Eggert, K., Csoti, I., Storch, A., Gasparini, F., Hariry, S., Johns, D., and Gomez-Mancilla, B. (2009) A randomized, controlled trial evaluating AFQ056 in reducing levodopa-induced dyskinesia in patients with Parkinson's disease. Abstracts of Papers, 13th International Congress of Parkinson's Disease and Movement Disorders, Paris, France, Abstract LB-05, The Movement Disorder Society: Milwaukee, WI.
49. Harris, G. Promise seen in drug for retardation syndrome. (April 30, 2010) New York Times, p A1.
50. AstraZeneca PLC: AstraZeneca Development Pipeline. Pipeline Summary (2009) July 30.
51. F. Hoffman-LaRoche, Ltd.: Roche Pipeline 2010. Pipeline Summary (2010) April 15.
52. Dove, P., Granberg, K., Isaac, M., Någård, M., and Slassi, A. (2009) 1,2,4-triazole ether derivatives as modulators of mGluR5. WO 2009/054785 A1.
53. Bratt, E., Granberg, K., Isaac, M., Någård, M., and Slassi, A. (2009) Amide linked heteroaromatic derivatives as modulators of mGluR5. WO 2009/054790 A1.
54. Isaac, M. and Wållberg, A. (2009) Amino 1,2,4-triazole derivatives as modulators of mGluR5. WO 2009/054794 A1.
55. Wensbo, D., Xin, T., Stefanac, T., Arora, J., Edwards, L., Isaac, M., Slassi, A., Stormann, T. M., McLeod, D. A., Kers, A., Malmberg, J., Oscarsson, K., Gyback, H., Johansson, M., Minidis, A., Waldman, M., Yngve, U., and Osterwall, C. New compounds. WO 2004/014881 A2.
56. Granberg, K. and Wållberg, A. (2009) 1,2,4-Triazole aryl N -oxides derivatives as modulators of mGluR5. WO 2009/054786 A1.
57. Bratt, E. and Granberg, K. (2009) 1,2,3-Triazole pyrrolidine derivatives as modulators of mGluR5. WO 2009/054789 A1.
58. Granberg, K., Slassi, A., Stefanac, T., and Wållberg, A. (2009) 1,2,4-Triazole carboxylic acid derivatives as modulators of mGluR5. WO 2009/054787 A1.
59. Granberg, K. and Holm, B. (2009) Aminopyridine derivatives as modulators of mGluR5. WO 2009/054792 A1.
60. Granberg, K., Holm, B., and Någård, M. (2009) Thiophene 1,2,4-triazole derivatives as modulators of mGluR5. WO 2009/054793 A1.
61. Granberg, K. and Holm, B. (2009) Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mGluR5. WO 2009/054791 A1.
62. Hansen, T. V., Wu, P., and Fokin, V. V. (2005) One-pot copper(I)-catalyzed synthesis of 3,5-disubstituted isoxazoles J. Org. Chem. 70, 7761-7764 (Pubitemid 41318540)
63. Granberg, K. and Holm, B. (2010) Sulphide bridged derivatives as modulators of mGluR5. WO 2010/123451 A1.
64. Corey, E. J., Bakshi, R. K., and Shibata, S. (1987) Highly enantioselective borane reduction of ketones catalyzed by chiral oxazaborolidines. Mechanism and synthetic implications J. Am. Chem. Soc. 109, 5551-5553
65. Wágner, G., Wéber, C., Nyéki, O., Nógrádi, K., Bielik, A., Molnár, L., Bobok, A., Horvath, A., Kiss, B., Kolok, S., Nagy, J., Kurkó, D., Gál, K., Greiner, I., Szombathelyi, Z., Keserü, G. M., and Domány, G. (2010) Hit to lead optimization of disubstituted oxadiazoles and tetrazoles as mGluR5 NAMs Bioorg. Med. Chem. Lett. 20, 3737-3741
66. 3H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5 Bioorg. Med. Chem. Lett. 12, 407-409 (Pubitemid 34113914)
67. Nissink, J. W. M. (2009) Simple size-independent measure of ligand efficiency J. Chem. Inf. Model. 49, 1617
68. Keserü, G. M. and Makara, G. M. (2009) The influence of lead discovery strategies on the properties of drug candidates Nat. Rev. Drug Discovery 8, 203-212
69. Galambos, J., Wágner, G., Nógrádi, K., Bielik, A., Molnár, L., Bobok, A., Horváth, A., Kiss, B., Kolok, S., Nagy, J., Kurkó, Bakk, M. L., Vastag, M., Sághy, K., Gyertyán, I., Gál, K., Greiner, I., Szombathelyi, Z., Keserü, G. M., and Domány, G. (2010) Carbamoyloximes as novel non-competitive mGlu5 receptor antagonists Bioorg. Med. Chem. Lett. 20, 4371-4375
70. Vogel, J. R., Beer, B., and Clody, D. E. (1971) A simple and reliable conflict procedure for testing anti-anxiety agents Psychopharmacology 21, 1-7
71. Pilla, M., Andreoli, M., Tessari, M., Delle-Fratte, S., Roth, A., Butler, S., Brown, F., Shah, P., Bettini, E., Cavallini, P., Benedetti, R., Minick, D., Smith, P., Tehan, B., D'Alessandro, P. D., Lorthioir, O., Ball, C., Garzya, V., Goodacre, C., and Watson, S. (2010) The identification of novel orally active mGluR5 antagonist GSK2210875 Bioorg. Med. Chem. Lett. 20, 7521-7524
72. Ferrari, L., Crestan, V., Sabattini, G, Vinco, F., Fontana, S., and Gozzi, A. (2010) Brain penetration of local anaesthetics in the rat: Implications for experimental neuroscience J. Neurosci. Methods 186, 143-149
73. Njung'e, K. and Handley, S. L. (1991) Evaluation of marble-burying behavior as a model of anxiety Pharmacol., Biochem. Behav. 38, 63-67
74. Britton, T. C., Dehlinger, V., Fivush, A. M., Hollinshead, S. P., and Vokits, B. P. (2009) 3-Indazolyl-4-pyridylisothiazoles. WO2009/123855 A1.
75. Dallmann, R., Steinlechner, S., von Hörsten, S., and Karl, T. (2006) Stress-induced hyperthermia in the rat: Comparison of classical and novel recording methods Lab. Anim. 40, 186-193
76. Jimenez, H. N., Li, G., Doller, D., Grenon, M., White, A. D., Guo, M., and Ma, G. (2010) Adamantyl diamide derivatives and uses of same. WO 2010/011570 A1.
77. 3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor Bioorg. Med. Chem. Lett. 13, 351
78. Moore, N. A., Rees, G., Sanger, G., and Tye, N. C. (1994) Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule Behav. Pharmacol. 5, 196-202 (Pubitemid 24153742)
79. Henrich, M., Weil, T., Müller, S., Nagel, J., Gravius, A., Kauss, V., Zemribo, R., and Erdmane, E. (2009) Pyrazolopyrimidines, a process for their preparation and their use as medicine. WO 2009/095254 A1.
80. Danysz, W., Dekundy, A., Hechenberger, M., Henrich, M., Jatzke, C., Nagel, J., Parsons, C. G. R., Weil, T., Fotins, J., Gutcaits, A., Kalvinsh, I., Zemribo, R., and Kauss, V. (2008) Pyrazolopyrimidines, a process for their preparation and the use as a medicine. WO 2008/015271 A1.
81. Kulkarni, S. S. and Newman, A. H. (2007) Design and synthesis of novel heterobiaryl amides as metabotropic glutamate receptor subtype 5 antagonists Bioorg. Med. Chem. Lett. 17, 2074-2079 (Pubitemid 46394535)
82. Kulkarni, S. S., Nightingale, B., Dersch, C. M., Rothman, R. B., and Newman, A. H. (2006) Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists Bioorg. Med. Chem. Lett. 16, 3371-3375 (Pubitemid 43792524)
83. Kulkarni, S. S., Zou, M.-F., Cao, J., Deschamps, J. R., Rodriguez, A. L., Conn, P. J., and Newman, A. H. (2009) Structure-activity relationships comparing N -(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted- arylethynyl)thiazoles as novel metabotrobic glutamate receptor subtype 5 antagonists J. Med. Chem. 52, 3563-3575
84. Kulkarni, S. S. and Newman, A. H. (2007) Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists Bioorg. Med. Chem. Lett. 17, 2987-2991 (Pubitemid 46722599)
85. Zhang, P., Zou, M.-F., Rodriguez, A. L., Conn, P. J., and Newman, A. H. (2010) Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic glutamate receptor subtype 5 Bioorg. Med. Chem. 18, 3026-3035
86. Boice, G. N., Savarin, C. G., Murry, J. A., Conrad, K., Matty, L., Corley, E. G., Smitrovich, J. H., and Hughes, D. (2004) An efficient synthesis of a highly functionalized 4-arylpiperidine Tetrahedron 60, 11367-11374 (Pubitemid 39516947)
87. Milbank, J. B. J., Knauer, C. S., Augelli-Szafran, C. E., Sakkab-Tan, A. T., Lin, K. K., Yamagata, K., Hoffman, J. K., Zhuang, N., Thomas, J., Galatsis, P., Wendt, J. A., Mickelson, J. W., Schwarz, R. D., Kinsora, J. J., Lotarski, S. M., Stakich, K., Gillespie, K. K., Lam, W. W., and Mutlib, A. E. (2007) Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists Bioorg. Med. Chem. Lett. 17, 4415-4418 (Pubitemid 47058971)
88. Sharma, S., Rodriguez, A. L., Conn, P. J, and Lindsley, C. W. (2008) Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: Unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold Bioorg. Med. Chem. Lett. 18, 4098-4101
89. Rodriguez, A. L., Nong, Y., Sekaran, N. K., Alagille, D., Tamagnan, G. D., and Conn, P. J. (2005) A close structural analog of 2-methyl-6- (phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators Mol. Pharmacol. 68, 1793-1802 (Pubitemid 41654362)
90. Spanka, C., Glatthar, R., Desrayaud, S., Fendt, M., Orain, D., Troxler, T., and Vranesic, I. (2010) Piperidyl amides as novel, potent and orally active mGlu5 receptor antagonists with anxiolytic-like activity Bioorg. Med. Chem. Lett. 20, 184-188
91. Bouwknecht, J. A., Olivier, B., and Paylor, R. E. (2007) The stress-induced hyperthermia paradigm as a physiological animal model for anxiety: A review of pharmacological and genetic studies in the mouse Neurosci. Biobehav. Rev. 31, 41-59 (Pubitemid 44880072)
92. Millan, M. J. and Brocco, M. (2003) The Vogel conflict test: Procedural aspects, γ-aminobutyric acid, glutamate and monoamines Eur. J. Pharmacol. 463, 67-96 (Pubitemid 36205073)
93. Davis, M., Falls, W. A., Campeau, S., and Kim, M. (1993) Fear-potentiated startle: A neural and pharmacological analysis Behav. Brain Res. 58, 175-198 (Pubitemid 24024057)
94. Davis, M. (1986) Pharmacological and anatomical analysis of fear conditioning using the fear-potentiated startle paradigm Behav. Neurosci. 100, 814-824 (Pubitemid 17002689)
95. Carcache, D., Vranesic, I., Blanz, J., Desrayaud, S., Fendt, M., and Glatthar, R. (2011) Benzimidazoles as potent and orally active mGlu5 receptor antagonists with an improved PK profile ACS Med. Chem. Lett. 2, 58-62
96. Hintermann, S., Vranesic, I., Allgeier, H., Brülisauer, A., Hoyer, D., Lemaire, M., Moenius, T., Urwyler, S., Whitebread, S., Gasparini, F., and Auberson, Y. (2007) ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: Identification, in vitro pharmacology, pharmacokinetic and biodistribution studies Bioorg. Med. Chem. 15, 903-914 (Pubitemid 44880714)
97. Burdi, D. F., Hunt, R., Fan, L., Hu, T., Wang, J., Guo, Z., Huang, Z., Wu, C., Hardy, L., Detheux, M., Orsini, M. A., Quinton, M. S., Lew, R., and Spear, K. (2010) Design, synthesis, and structure-activity relationships of novel bicyclic azole-amines as negative allosteric modulators of metabotropic glutamate receptors J. Med. Chem. 53, 7107-7118
98. Rodriguez, A. L., Williams, R., Zhou, Y., Lindsley, S. R., Le, U., Grier, M. D., Weaver, C. D., Conn, P. J., and Lindsley, C. W. (2009) Discovery and SAR of novel mGluR5 non-competitive antagonists not based on an MPEP chemotype Bioorg. Med. Chem. Lett. 19, 3209-3213
99. 5 Bioorg. Med. Chem. Lett. 19, 6623-6626
100. Shipe, W. D., Wolkenberg, S. E., and Lindsley, C. W. (2005) Accelerating lead development by microwave-enhanced medicinal chemistry Drug Discovery Today: Technol. 2, 155
101. Zhou, Y., Rodriguez, A. L., Williams, R., Weaver, C. D., Conn, P. J., and Lindsley, C. W. (2009) Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS Bioorg. Med. Chem. Lett. 19, 6502-6506
102. Rodriguez, A. L., Grier, M. D., Jones, C. K., Herman, E. J., Kane, A. S., Smith, R. L., Williams, R., Zhou, Y., Marlo, J. E., Days, E. L., Blatt, T. N., Jadhav, S., Menon, U. N., Vinson, P. N., Rook, J. M., Stauffer, S. R., Niswender, C. M., Lindsley, C. W., Weaver, C. D., and Conn, P. J. (2010) Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity Mol. Pharmacol. 78, 1105-1123
103. Van Wagenen, B. C., Stormann, T. M., Moe, S. T., Sheehan, S. M., McLeod, D. A., Smith, D. L., Isaac, M. B., and Slassi, A. (2001) Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists. WO 01/12627 A1.
104. 5: Identification of easily prepared tool compounds with CNS exposure in rats Bioorg. Med. Chem. Lett. 20, 4390-4394